^Back To Top

foto1 foto2 foto3 foto4 foto5


Our news

  • 04/07/2017: Pharegis analytics: advantages and possibilities of Eurasian Economic Union (EEU) 2017 requirements for registration of medical drugs and devices.
  • 03/30/2017: Pharegis analytics: Russian GMP inspections - possibilities and key elements.
  • 05/20/2016: Pharegis implemented full integration of Russian GMP services to API and finished product registration services.

Contact us

enzh-CNfrdeitjakoptrues

Regulatory Events Russia

December 2018
S M T W T F S
25 26 27 28 29 30 1
2 3 4 5 6 7 8
9 10 11 12 13 14 15
16 17 18 19 20 21 22
23 24 25 26 27 28 29
30 31 1 2 3 4 5
January 2019
S M T W T F S
30 31 1 2 3 4 5
6 7 8 9 10 11 12
13 14 15 16 17 18 19
20 21 22 23 24 25 26
27 28 29 30 31 1 2

Russian Regulatory News

Preclinical studies for biopharma products (original biopharmaceuticals, biosimilars, vaccines, monoclonal antibodies, immunoglobulins, biopharmaceutical orphane drugs) by regulatory CRO Pharegis in Russia

Registration of biopharmaceutical drugs in Russia

assumes quite complex set of activities. Due to strict and spedific regulatory requirements in Russia to biopharmaceuticals e.g. biosimilar products, in particular, completed preclinical studies program that is needed in frames of registration dossier for a biopharmaceutical product can be much more sophisticated and challenging than set of standard tests for an original “traditional” pharmaceutical.

Depending of type and clinical pharmacology class of biopharma product its preclinical programs should have following studies:

  1. Pharmacodynamics - in vitro and/or in vivo
  2. Pharmacokinetics - in vitro and/or in vivo
  3. Immunogenicity
  4. Immunotoxicity
  5. Safety pharmacology for key systems of organs
  6. Reproductive toxicity
  7. Cancerogenicity
  8. Mutagenicity
  9. Drug interaction safety
  10. Other specific studies

Specific preclinical program is required for registration of new vaccines in Russia.

For biotechnological medicines like monoclonal antibodies, recombinant protein-based pharmaceuticals and other product produced by cell lines, it is needed to present quality confirming documents for every stage of cell bank growth and purification as well as every source material used in biotechnological manufacturing.

 

Our experts have comprehensive experience in managing and conduction of preclinical studies programs for biopharmaceuticals in various GLP-compliant centers all over Russian Federation. Also we can analyze your existing preclinical studies portfolio, advising best way to handle specific studies missing for registration in Russia.

We provide fast and free calculation of your preclinical program budget and timeline. Send us your request or simply call us and our experts will discuss every detail of your project with you and you will receive working solution that will bring you Clear Regulatory Answers for your business.

SHARE THIS BY: